Skip to content
Study details
Enrolling now

64Cu-SAR-bisPSMA Trial for Prostate Cancer

Clarity Pharmaceuticals Ltd
NCT IDNCT06970847ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

220

Study length

about 1.6 years

Ages

18+

Sex

Male only

Locations

24 sites in AR, AZ, CA +15

What this study is about

Researchers are testing whether 64Cu-SAR-bisPSMA can help find prostate cancer that has returned after treatment. The trial will involve men with prostate cancer who have had previous treatments like surgery, radiation, or brachytherapy. Participants will be followed for about a year and a half.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take 64Cu-SAR-bisPSMA

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: To determine the efficacy of 64Cu-SAR-bisPSMA PET/CT in participants with negative or equivocal conventional imaging at baseline, To investigate the safety and tolerability of 64-CuSAR-bisPSMA

Body systems

Oncology